{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:40:04Z","timestamp":1790430004742,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Federation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oncolytic viruses offer a promising approach to tumor treatment. These viruses not only have a direct lytic effect on tumor cells but can also modify the tumor microenvironment and activate antitumor immunity. Due to their high pathogenicity, flaviviruses have often been overlooked as potential antitumor agents. However, with recent advancements in genetic engineering techniques, an extensive history with vaccine strains, and the development of new attenuated vaccine strains, there has been a renewed interest in the Flavivirus genus. Flaviviruses can be genetically modified to express transgenes at acceptable levels, and the stability of such constructs has been greatly improving over the years. The key advantages of flaviviruses include their reproduction cycle occurring entirely within the cytoplasm (avoiding genome integration) and their ability to cross the blood\u2013brain barrier, facilitating the systemic delivery of oncolytics against brain tumors. So far, the direct lytic effects and immunomodulatory activities of many flaviviruses have been widely studied in experimental animal models across various types of tumors. In this review, we delve into the findings of these studies and contemplate the promising potential of flaviviruses in oncolytic therapies.<\/jats:p>","DOI":"10.3390\/v15101973","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:44:42Z","timestamp":1695354282000},"page":"1973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Flaviviruses in AntiTumor Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Alina S.","family":"Nazarenko","sequence":"first","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail F.","family":"Vorovitch","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia K.","family":"Biryukova","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay B.","family":"Pestov","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Orlova","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolai A.","family":"Barlev","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda M.","family":"Kolyasnikova","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydar A.","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia"},{"name":"Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17460441.2021.1850689","article-title":"The Discovery and Development of Oncolytic Viruses: Are They the Future of Cancer Immunotherapy?","volume":"16","author":"Zhang","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"688755","DOI":"10.3389\/fonc.2021.688755","article-title":"Repurposing Infectious Diseases Vaccines against Cancer","volume":"11","author":"Vandeborne","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering Strategies to Enhance Oncolytic Viruses in Cancer Immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1038\/s41467-023-38651-x","article-title":"Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies","volume":"14","author":"Azad","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1188526","DOI":"10.3389\/fmicb.2023.1188526","article-title":"Development and application of oncolytic viruses as the nemesis of tumor cells","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: Challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ji, Q., Wu, Y., Albers, A., Fang, M., and Qian, X. (2022). Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091811"},{"key":"ref_11","first-page":"266","article-title":"Anti-Cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future","volume":"24","author":"Kolyasnikova","year":"2022","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.drudis.2020.09.014","article-title":"Gene therapy in solid tumors: Trends in trials in China and beyond","volume":"26","author":"Chen","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nettelbeck, D.M., Leber, M.F., Altomonte, J., Angelova, A., Beil, J., Berchtold, S., Delic, M., Eberle, J., Ehrhardt, A., and Engeland, C.E. (2021). Virotherapy in Germany\u2014Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses, 13.","DOI":"10.3390\/v13081420"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jjco\/hyy170","article-title":"Oncolytic virus therapy in Japan: Progress in clinical trials and future perspectives","volume":"49","author":"Taguchi","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_15","first-page":"e40742","article-title":"The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy","volume":"15","author":"Zolaly","year":"2023","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43856-022-00098-4","article-title":"Advances in oncolytic virotherapy","volume":"2","author":"Russell","year":"2022","journal-title":"Commun. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, T., Jou, T.H.-T., Hsin, J., Wang, Z., Huang, K., Ye, J., Yin, H., and Xing, Y. (2023). Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031098"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to Treat Immune Hot, Altered and Cold Tumours with Combination Immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Cerullo","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1084\/jem.20171093","article-title":"Zika Virus Has Oncolytic Activity against Glioblastoma Stem Cells","volume":"214","author":"Zhu","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e01683-18","DOI":"10.1128\/mBio.01683-18","article-title":"Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate","volume":"9","author":"Chen","year":"2018","journal-title":"mBio"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Trus, I., Berube, N., Jiang, P., Rak, J., Gerdts, V., and Karniychuk, U. (2020). Zika Virus with Increased CpG Dinucleotide Frequencies Shows Oncolytic Activity in Glioblastoma Stem Cells. Viruses, 12.","DOI":"10.3390\/v12050579"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1021\/acs.chemrev.7b00719","article-title":"Biochemistry and Molecular Biology of Flaviviruses","volume":"118","author":"Barrows","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_26","unstructured":"Maramorosch, K., Chambers, T.J., Monath, T.P., Shatkin, A.J., and Murphy, F.A. (2003). The Flaviviruses: Structure, Replication and Evolution, Elsevier."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.virol.2022.02.001","article-title":"The interactions of flaviviruses with cellular receptors: Implications for virus entry","volume":"568","author":"Anwar","year":"2022","journal-title":"Virology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.coviro.2014.09.020","article-title":"Coupling of Replication and Assembly in Flaviviruses","volume":"9","author":"Sirohi","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0065-3527(03)59002-9","article-title":"Molecular biology of flaviviruses","volume":"59","author":"Lindenbach","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/brv.12034","article-title":"Glycosaminoglycans in Infectious Disease","volume":"88","author":"Kamhi","year":"2013","journal-title":"Biol. Rev."},{"key":"ref_31","first-page":"69","article-title":"Flavivirus Entry Receptors: An Update","volume":"6","author":"Meertens","year":"2014","journal-title":"Viruses"},{"key":"ref_32","unstructured":"Dobler, P.D.G., Erber, D.W., Br\u00f6ker, D.M., and Schmit, P.D.H.-J. (2019). The TBE Book, Global Health Press. [2nd ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/1097-0142(195103)4:2<375::AID-CNCR2820040227>3.0.CO;2-A","article-title":"Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis","volume":"4","author":"Moore","year":"1951","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O","article-title":"The destructive effect of the virus of russian far east encephalitis on the transplantable mouse sarcoma 180","volume":"2","author":"Moore","year":"1949","journal-title":"Cancer"},{"key":"ref_35","first-page":"30","article-title":"Comparative study of the viruses of the tick encephalitis group in HeLa cell cultures","volume":"5","author":"Levkovich","year":"1960","journal-title":"Vopr. Virusol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/BF00786290","article-title":"Inhibitory action of viruses of the tick-borne encephalitis complex differing in neurovirulence on mouse tumors in vivo","volume":"64","author":"Levkovich","year":"1967","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1099\/vir.0.010058-0","article-title":"Morphological changes in human neural cells following tick-borne encephalitis virus infection","volume":"90","author":"Ahantarig","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_38","first-page":"539","article-title":"A study of the features of reproduction in tumor cells in vitro and in vivo of different viruses of the tick-borne encephalitis complex, possessing various degress of neurovirulence","volume":"11","author":"Sergeeva","year":"1966","journal-title":"Vopr. Virusol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1097-0142(195103)4:2<367::AID-CNCR2820040226>3.0.CO;2-8","article-title":"The effect of St. Louis encephalitis virus on transplantable Crocker mouse sarcoma 180","volume":"4","author":"Buckley","year":"1951","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/iai.37.1.23-27.1982","article-title":"Virus inoculation in mice bearing Ehrlich ascitic tumors: Antigen production and tumor regression","volume":"37","author":"Mettler","year":"1982","journal-title":"Infect. Immun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/bmj.1.5482.258","article-title":"Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: A clinical and laboratory study of 28 patients","volume":"1","author":"Webb","year":"1966","journal-title":"Br. Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e10375","DOI":"10.15252\/emmm.201910375","article-title":"Repurposing the yellow fever vaccine for intratumoral immunotherapy","volume":"12","author":"Aznar","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"982180","DOI":"10.3389\/fimmu.2023.982180","article-title":"Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity","volume":"14","author":"Qi","year":"2022","journal-title":"Front Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nrneurol.2017.138","article-title":"Neuro-oncology: A new role for Zika virus in glioblastoma therapy?","volume":"13","author":"Wood","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114094","DOI":"10.1016\/j.biopha.2022.114094","article-title":"Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response","volume":"158","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A Review of Dengvaxia\u00ae: Development to Deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","article-title":"Dengue Vaccines: An Update","volume":"36","author":"Salazar","year":"2022","journal-title":"BioDrugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40506-020-00242-5","article-title":"Japanese Encephalitis Vaccines","volume":"12","author":"Satchidanandam","year":"2020","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40121-013-0018-2","article-title":"Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine","volume":"2","author":"Chin","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kaiser, J.A., and Barrett, A.D.T. (2019). Twenty Years of Progress Toward West Nile Virus Vaccine Development. Viruses, 11.","DOI":"10.3390\/v11090823"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13206","DOI":"10.1038\/s41598-018-31375-9","article-title":"Chimeric Yellow Fever 17D-Zika Virus (ChimeriVax-Zika) as a Live-Attenuated Zika Virus Vaccine","volume":"8","author":"Goncalvez","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41467-018-02975-w","article-title":"Development of a Chimeric Zika Vaccine Using a Licensed Live-Attenuated Flavivirus Vaccine as Backbone","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1038\/s41467-019-11866-7","article-title":"Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice","volume":"10","author":"Figueiredo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.aaf6116","article-title":"Zika virus impairs growth in human neurospheres and brain organoids","volume":"352","author":"Garcez","year":"2016","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.stem.2016.03.012","article-title":"Expression Analysis Highlights AXL as a Candidate Zika Virus Entry Receptor in Neural Stem Cells","volume":"18","author":"Nowakowski","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.stem.2016.11.011","article-title":"Genetic Ablation of AXL Does Not Protect Human Neural Progenitor Cells and Cerebral Organoids from Zika Virus Infection","volume":"19","author":"Wells","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.33249","article-title":"Novel insights into the function of CD24: A driving force in cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mazar, J., Li, Y., Rosado, A., Phelan, P., Kedarinath, K., Parks, G.D., Alexander, K.A., and Westmoreland, T.J. (2018). Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200358"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbrc.2019.06.064","article-title":"Zika virus NS5 protein inhibits cell growth and invasion of glioma","volume":"516","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ni1102-1013","article-title":"To kill or be killed: Viral evasion of apoptosis","volume":"3","author":"Benedict","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/2049-632X.12178","article-title":"The role of viral persistence in flavivirus biology","volume":"71","author":"Mlera","year":"2014","journal-title":"Pathog. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and Clearance of Apoptotic Cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the Immune System: The Dynamic Duo","volume":"17","author":"Franco","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_69","first-page":"e144619","article-title":"Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade","volume":"6","author":"Nair","year":"2021","journal-title":"J. Clin. Investig. Insight"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fonc.2019.00963","article-title":"Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets","volume":"9","author":"Taylor","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1158\/0008-5472.CAN-17-3201","article-title":"Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells In Vitro and In Vivo","volume":"78","author":"Kaid","year":"2018","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ymthe.2020.03.004","article-title":"Safety, Tumor Reduction, and Clinical Impact of Zika Virus Injection in Dogs with Advanced-Stage Brain Tumors","volume":"28","author":"Kaid","year":"2020","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.stem.2019.11.016","article-title":"Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin \u03b1v\u03b25 Axis","volume":"26","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.omto.2022.01.011","article-title":"Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma","volume":"24","author":"Chen","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Macip","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/acsmedchemlett.5b00011","article-title":"Discovery of Novel Isatin-Based p53 Inducers","volume":"6","author":"Davidovich","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.18632\/genesandcancer.123","article-title":"E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells","volume":"7","author":"Daks","year":"2016","journal-title":"Genes Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25843","DOI":"10.18632\/oncotarget.4584","article-title":"KMT Set7\/9 affects genotoxic stress response via the Mdm2 axis","volume":"6","author":"Lezina","year":"2015","journal-title":"Oncotarget"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7184","DOI":"10.2741\/3220","article-title":"Role of proteasomes in transcription and their regulation by covalent modifications","volume":"13","author":"Mittenberg","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"World Health Organization (2017). WHO position on the use of fractional doses\u2014June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper\u2014June 2013. Vaccine, 35, 5751\u20135752.","DOI":"10.1016\/j.vaccine.2017.06.087"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1128\/JVI.74.19.9197-9205.2000","article-title":"Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases","volume":"74","author":"McAllister","year":"2000","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.1951.s1-31.724","article-title":"West Nile, Ilheus, and Bunyamwera Virus Infections in Man","volume":"31","author":"Southam","year":"1951","journal-title":"Am. J. Trop. Med."},{"key":"ref_83","first-page":"1025","article-title":"Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus","volume":"5","author":"Southam","year":"1952","journal-title":"ACS J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e14108","DOI":"10.15252\/emmm.202114108","article-title":"Rational design of West Nile virus vaccine through large replacement of 3\u2032 UTR with internal poly(A)","volume":"13","author":"Zhang","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2001.tb02693.x","article-title":"Kunjin virus: An Australian variant of West Nile?","volume":"951","author":"Hall","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/JVI.78.1.531-538.2004","article-title":"Tetracycline-inducible packaging cell line for production of flavivirus replicon particles","volume":"78","author":"Harvey","year":"2004","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1128\/JVI.72.7.5967-5977.1998","article-title":"Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans","volume":"72","author":"Khromykh","year":"1998","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2008.169","article-title":"A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy","volume":"16","author":"Smeenk","year":"2009","journal-title":"Gene Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.virol.2003.10.032","article-title":"Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour","volume":"319","author":"Herd","year":"2004","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.77.14.7796-7803.2003","article-title":"Kunjin virus replicon vectors for human immunodeficiency virus vaccine development","volume":"77","author":"Harvey","year":"2003","journal-title":"J. Virol."},{"key":"ref_91","first-page":"165","article-title":"West Nile virus capsid protein induces p53-mediated apoptosis via the sequestration of HDM2 to the nucleolus","volume":"10","author":"Yang","year":"2007","journal-title":"Cell. Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41420-018-0120-z","article-title":"Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors","volume":"4","author":"Bulatov","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","article-title":"MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models","volume":"73","author":"Tovar","year":"2013","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.vaccine.2010.02.105","article-title":"Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Goldufsky, J.W., Daniels, P., Williams, M.D., Gupta, K., Lyday, B., Chen, T., Singh, G., Zloza, A., and Marzo, A.L. (2022). Attenuated Dengue Virus PV001-DV Induces Oncolytic Cell Death and Potent Anti-Tumor Immunity. bioRxiv, preprint.","DOI":"10.1101\/2022.07.05.498884"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/jmv.20004","article-title":"Apoptosis in dengue virus infected liver cell lines HepG2 and Hep3B","volume":"72","author":"Thongtan","year":"2004","journal-title":"J. Med. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11262-023-01985-1","article-title":"Identification and Validation of Ferroptosis-Related Genes in Patients Infected with Dengue Virus: Implication in the Pathogenesis of DENV","volume":"59","author":"Li","year":"2023","journal-title":"Virus Genes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/B978-0-444-53488-0.00026-2","article-title":"Chapter 26\u2014Japanese encephalitis virus infection","volume":"Volume 123","author":"Tselis","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Mehlhorn, H., and Heukelbach, J. (2022). Infectious Tropical Diseases and One Health in Latin America, Springer International Publishing. Parasitology Research Monographs.","DOI":"10.1007\/978-3-030-99712-0"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e2021055522","DOI":"10.1542\/peds.2021-055522","article-title":"Dengue: A Growing Problem With New Interventions","volume":"149","author":"Wong","year":"2022","journal-title":"Pediatrics"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0264-410X(02)00819-8","article-title":"Diagnosis of tick-borne encephalitis","volume":"21","author":"Holzmann","year":"2003","journal-title":"Vaccine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S145262","article-title":"Oncolytic virus delivery: From nano-pharmacodynamics to enhanced oncolytic effect","volume":"6","author":"Yokoda","year":"2017","journal-title":"Oncolytic Virotherapy"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S186337","article-title":"Virus\u2013Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development","volume":"9","author":"Jayawardena","year":"2020","journal-title":"Oncolytic Virotherapy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-018-0061-9","article-title":"Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation","volume":"3","author":"Barrett","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2019.01.014","article-title":"Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines","volume":"164","author":"Ruzek","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Dutta, S.K., and Langenburg, T. (2023). A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses, 15.","DOI":"10.3390\/v15040860"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/10\/1973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:26Z","timestamp":1760129726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/10\/1973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":107,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["v15101973"],"URL":"https:\/\/doi.org\/10.3390\/v15101973","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}